Bayer’s Stivarga patent targeted in IPR petition

Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review (IPR) petition challenging a patent owned by German pharmaceutical company Bayer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.

Americas

Novartis takes aim at Tafinlar generic in latest suit

9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

More features

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

Novartis takes aim at Tafinlar generic in latest suit

Semaglutide patent battle heats up with new blow for Novo in India

Wilson Sonsini senior counsel moves to a rival firm

AstraZeneca partners with Chinese firm ahead of next obesity race

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

Bayer’s Stivarga patent targeted in IPR petition

More on this story

Editor's picks

Editor's picks

More features